Weekly Recap | Aveanna Healthcare -2.91%, most brokers rate it buy

The Week

Aveanna Healthcare (AVAH) closed the week at $13.67, down 2.91% from the prior Friday. The S&P 500 slipped 0.08%, leaving the stock roughly 2.83 percentage points behind. Price action shaped up as a failed rally: Monday touched $14.695 intraday, Tuesday and Wednesday held a $14.1-$14.7 range, Thursday slid to $13.97, and Friday made a low of $13.585 before settling at $13.67. Weekly amplitude was 7.88%, and average daily volume ran more than 73% above the two-month median.

Key Events

The week’s company-specific news was thin but directional. On Tuesday, 15 September, reports noted that Aveanna had hit a 12-month high after an analyst upgrade. A Cramer lightning-round item that shared the same date was unrelated to the company and is not material here. On Wednesday, 16 September, an article asked whether the earlier earnings beat changed the bull case for AVAH; it referenced the prior quarter’s results rather than a fresh report this week.

Analyst Ratings

Across 11 covering institutions, 6 rate the stock buy, 2 rate it overweight, and 3 rate it hold, leaving 8 at buy or overweight and none at underweight or sell. The consensus rating is buy, with a consensus target of $14.60, about 6.8% above the $13.67 close. Targets range from $13.00 to $16.00, a reasonably tight band. Within the 531-name healthcare services group, Aveanna’s rating rank is 15, above the median.

The Week Ahead

There are no Aveanna earnings on the calendar for next week. The watch list is mostly macro: the Richmond Fed composite index on Tuesday, 22 September, then jobless claims, the current-account balance, new home sales annual rate, and EIA natural gas storage on Thursday, 24 September. For a healthcare services name, these matter mainly through rate expectations and broader risk appetite.

In Short

Price fell modestly despite a supportive ratings backdrop: consensus remains buy, the target sits above spot, and no analyst carries a sell or underweight. Money flow was split on the latest session, with large-lot money on the sell side while medium and small flows leaned in. Valuation shows a 10.86x P/E against a high 10.36x P/B, the latter reflecting an asset-light model. The near-term question is whether price can hold near the $14.7 range high with volume support, and how rate-sensitive positioning evolves around the macro prints.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.